Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Psoriatic Arthritis (FUTURE 4)
NCT02294227Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2015
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of secukinumab in psoriatic arthritis (PsA), psoriasis, sponsored by Novartis. Started May 2015; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)psoriasis
Beyond the preview
Go deeper on NCT02294227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02294227.